Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
April 29 2021 - 5:00AM
Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph
T. Kennedy has informed the board of directors of his decision to
retire as executive vice president, general counsel and strategic
initiatives. A search is underway at Amarin for a new general
counsel. Mr. Kennedy has agreed to continue in his role until a
replacement is hired and manage certain legacy matters through the
end of 2021. He is committed to a smooth transition of
responsibilities.
Dr. Lars Ekman, Chairman of Amarin’s Board of
Directors, commented, “The board and management at Amarin are
profoundly grateful to Joe for his service to the company over the
last decade. As EVP at Amarin, Joe’s critical thinking, ingenuity
and persistence repeatedly played a pivotal role in the development
of the company from clinical stage to a commercial multinational.
To enable Amarin to progress on its mission, Joe championed
solutions on issues that long vexed the pharmaceutical industry in
areas as diverse as decriminalizing communication of truthful and
non-misleading drug information under the First Amendment, expanded
regulatory exclusivity incentives for naturally derived products
and competitive claim advocacy. We look forward to Joe’s guidance
as we hire a new general counsel at Amarin and work together to
help accelerate the company’s growth trajectory
worldwide.”
“With a groundbreaking drug, untapped global
markets and a talented and seasoned team in place in every company
discipline, I have no doubt that Amarin’s best years lie ahead,”
said Mr. Kennedy. “Working with the many talented colleagues at
Amarin has been a privilege and an honor. I look forward to
ensuring a smooth transition.”
About Amarin
Amarin is an innovative pharmaceutical company
leading a new paradigm in cardiovascular disease management. From
our scientific research foundation to our focus on clinical trials,
and now our commercial expansion, we are evolving and growing
rapidly. Amarin has offices in Bridgewater, New Jersey in the
United States, Dublin in Ireland, and Zug in Switzerland as well as
commercial partners and suppliers around the world. We are
committed to rethinking cardiovascular risk through the advancement
of scientific understanding of the impact on society of significant
residual risk that exists beyond traditional therapies, such as
statins for cholesterol management.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements about expectations for future
progress at Amarin, accelerated growth trajectory and planned
smooth management transition. These forward-looking statements are
not promises or guarantees and involve substantial risks and
uncertainties that may individually or together impact the matters
herein and cause actual results, events and performance to differ
materially from such forward looking statements. Among the factors
that could cause actual results to differ materially from those
described or projected herein include the following: events that
could impact future regulatory assessment, such as delays due to
COVID-19 restrictions, later arising data, regulatory reviews and
pricing assessments, and the successful implementation of
commercialization plans or other information, uncertainties
associated with litigation generally and patent litigation
specifically; Amarin's ability generally to maintain adequate
patent protection and successfully enforce patent claims against
third parties; and uncertainties associated generally with research
and development and regulatory submissions, reviews, action dates
and approvals. A further list and description of these risks,
uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities
and Exchange Commission, including its most recent quarterly report
on Form 10-Q. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Amarin undertakes no obligation
to update or revise the information contained in this press
release, whether as a result of new information, future events or
circumstances or otherwise. Amarin’s forward-looking statements do
not reflect the potential impact of significant transactions the
company may enter into, such as mergers, acquisitions,
dispositions, joint ventures or any material agreements that Amarin
may enter into, amend or terminate.
Availability of Other Information About
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor relations website
(investor.amarincorp.com), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media, and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:Investor RelationsAmarin
Corporation plcIn U.S.: +1 (908) 719-1315 IR@amarincorp.com
(investor inquiries)
Solebury Troutamarinir@troutgroup.com
Media Inquiries:CommunicationsAmarin Corporation
plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media
inquiries)
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From May 2023 to May 2024